Singapore markets closed

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.67+0.16 (+1.88%)
At close: 04:00PM EDT
9.10 +0.43 (+4.96%)
After hours: 04:19PM EDT

Phathom Pharmaceuticals, Inc.

100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees77

Key executives

NameTitlePayExercisedYear born
Ms. Terrie J. CurranPres, CEO & Director978.38kN/A1969
Mr. David A. SocksCo-Founder & Director132.05kN/A1975
Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder & COO791.72kN/A1960
Mr. Anthony J. GuzzoChief Accounting Officer468.27kN/A1973
Mr. Aditya Kohli Ph.D.Co-FounderN/AN/A1988
Ms. Molly Henderson CPA, MBAChief Financial & Bus. OfficerN/AN/A1971
Mr. Joseph Hand J.D.Chief Admin. OfficerN/AN/AN/A
Mr. Lawrence Miller Esq., J.D.Gen. Counsel & Sec.N/AN/AN/A
Mr. Tom HarrisChief Devel. Sciences OfficerN/AN/AN/A
Dr. Eckhard Leifke M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Corporate governance

Phathom Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.